Reply to Office Action of February 12, 2008

AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A method for depigmenting or lightening the epidermis with a

protective and regenerate effect comprising topically applying at least one lyophilisate of

dedifferentiated plant cells to depigment or to lighten wherein said dedifferentiated plant cells

are halophile plant cells.

2. (Previously Presented) The method according to claim 1, wherein the dedifferentiated plant

cells are obtained by in vitro culture.

3. (Previously Presented) The method according to claim 2, wherein the dedifferentiated plant

cells obtained by in vitro culture are cell lines.

4. (Canceled)

5. (Previously Presented) The method according to claim 1, wherein the halophile plant is

Criste Marine.

6. (Previously Presented) The method according to claim 1, wherein the lyophilisate

depigments or lightens the epidermis by blocking the tyrosinase activity.

7. (Previously Presented) The method according to claim 1, wherein the lyophilisate protects

the epidermis by an anti-radical effect.

8. (Previously Presented) The method according to claim 1, wherein the lyophilisate

regenerates the epidermis by a stimulating effect on the proliferation of the cells of the

epidermal basal layer.

9. (Previously Presented) The method according to claim 1, wherein the lyophilisate

regenerates the epidermis by an inhibitory effect on the epidermal differentiation.

10. (Currently Amended) A topically applied cosmetic or pharmaceutical composition comprising

6

LRS/whg

at least one lyophilisate of dedifferentiated plant cells in a physiologically acceptable base, wherein said dedifferentiated plant cells are halophylic halophytic plant cells.

- 11. (Previously Presented) The topically-applied cosmetic or pharmaceutical composition according to claim 10, wherein the at least one lyophilisate is from 0.05% to 2% of the composition.
- 12. **(Currently Amended)** The topically-applied cosmetic or pharmaceutical composition according to claim 1 claim 10, wherein the at least one lyophilisate is from 0.1% to 1% of the composition.
- 13. **(Previously Presented)** The topically-applied cosmetic or pharmaceutical composition according to claim 10, wherein the at least one lyophilisate is 0.5% of the composition.
- 14. **(Presently Amended)** The composition according to any one of claims 10 to 13, wherein said composition rejuvenates the skin.
- 15. (Previously Presented) The composition according to any one of claims 10 to 13, wherein said composition treats pigment spots.
- 16. **(Previously Presented)** The composition according to any one of claims 10 to 13, wherein said compostion lightens black or asian skin.
- 17. **(Previously Presented)** The composition according to claim 10, wherein the dedifferentiated plant cells are obtained by in vitro culture.
- 18. **(Previously Presented)** The composition according to claim 17, wherein the dedifferentiated plant cells obtained by in vitro culture are cell lines.
- 19. (Canceled)
- 20. (Currently Amended) The composition according to claim 10, wherein the halophile

Docket No.: 0040-0164PUS1

halophytic plant-is cells are Criste Marine cells.

21. (Previously Presented) The composition according to claim 10, wherein the lyophilisate blocks tyrosinase activity.

- 22. (Previously Presented) The composition according to claim 10, wherein the lyophilisate has an anti-radical effect.
- 23. (**Previously Presented**) The composition according to claim 10, wherein the lyophilisate stimulates the proliferation of epidermal basal layer cells.
- 24. (**Previously Presented**) The composition according to claim 10, wherein the lyophilisate inhibits epidermal differentiation.
- 25. (New) A typically applied cosmetic or pharmaceutical composition comprising at least one lyophilisate of dedifferentiated plant cells in a physiologically acceptable base, wherein said dedifferentiated plant cells are halophytic plant cells from a halophyte plant selected from the group consisting of Salicornia ramossisima (Salicorne), Sueda vera, Beta maritima, obione portulacoides, Armeria maritima, Crithmum maritimum (Criste Marine), Ophrys sphegodes, Artemia vulgaris, Muscaris comosum, Eryngium maritimum, Sanguisorba minor, Cochlearia officinalis, Fumaria officinalis, Vincetoxicum fullonum, Dipsacus fullonum, Heracleum spondylium, Inula crithmoides, Inula brittanica, and Inula viscosa.
- 26. (New) The topically-applied cosmetic or pharmaceutical composition according to claim 25, wherein the at least one lyophilisate is from 0.05% to 2% of the composition.
- 27. (New) The topically-applied cosmetic or pharmaceutical composition according to claim 25, wherein the at least one lyophilisate is from 0.1% to 1% of the composition.
- 28. (New) The topically-applied cosmetic or pharmaceutical composition according to claim 25, wherein the at least one lyophilisate is 0.5% of the composition.